medigraphic.com
ISSN 1405-1710 (Print)

2012, Number 3

Next >>

Rev Cent Dermatol Pascua 2012; 21 (3)

Treatment of alopecia areata in plates with 0.075% capsaicin ointment

Gaxiola-Álvarez E, Jurado Santa-Cruz F, Domínguez-Gómez MA, Peralta-Pedrero ML

Language: Spanish
References: 29
Page: 91-98
PDF size: 148.13 Kb.


ABSTRACT

Introduction: Alopecia areata is considered a multifactorial disease, with genetic predisposition, wich pathogenically is a tissue specific, autoimmune disease that affects hair follicules in any body part, preferably in the scalp. Stress play a key role in the initiation and progression of AA wich has lead to investigation of pathways that link the nervus system and the immune system like the one that involves the neuropeptides substance P (SP), calcitonin-gene related peptide (CGRP), vasoactive intestinal (VIP) peptide as immunomodulators. In this base is postulated that topical capsaicin induce release of SP and after repeated application causes transient depletion of SP , leading to de growing of the hair follicle limiting the infl ammatory cascade. Methods: Randomized clinical, triple blind, placebo-controlled trial, effectiveness of capsaicin 0.075% in the treatment of alopecia areata. Results and discussion: These result are applicable to patients with diagnosis of AA SALT1 (with less than 25% of severity) and SALT2 (between 26 and 49%) (SALT S2) wich clinically means mild AA. There was no statistically significative difference when we compare number of patches, SALT score, Hair density per cm2, and greater diameter at 12 weeks at the beginning and in the end of the trial. Conclusion: There was no statistically significative results between capsaicin 0.075% versus placebo in patients with mild AA in patches.


REFERENCES

  1. Gilhar A, Etzioni A, Paus R. Alopecia areata. N Engl J Med 2012; 366: 1515-1525.

  2. Sharma VK, Dawn G, Kumar B. Profi le of alopecia areata in Northern India. Int J Dermatol 1996; 35: 22-27.

  3. Olsen EA. Hair, in Fitzpatrick’s Dermatology in General Medicine. In: Freedberg IM. New York: McGraw-Hill,2003: 641-643.

  4. Gilhar A, Kalish R. Alopecia areata: a tissue specifi c autoimmune disease of the hair follicle. Autoimmunity Reviews 2006; 5: 64-69.

  5. Tan E, Tay YK, Goh CL, Chin Giam Y. The pattern and profi le of alopecia areata in Singapore a study of 219 Asians. Int J Dermatol 2002; 41: 748-753.

  6. Safavi KH, Muller SA, Suman VJ, Moshell AN, Melton L. Incidence of alopecia areata in Olmsted County, Minnesota 1975 through 1989. Mayo Clin Proc 1995; 70: 628-633.

  7. Wasserman D, Guzmán-Sánchez DA, Scott K, McMichael A. Alopecia areata. Int J Dermatol 2007; 46: 121-131.

  8. Nanda A, Al-Fouzan AS, Al-Hasawi F. Alopecia areata in children: a clinical profi le. Pediatr Dermatol 2002; 19: 482-485.

  9. Price VH. Alopecia areata: clinical aspects. J Invest Dermatol 1991; 96: 68S.

  10. de Berker DAR, Messenger AG, Sinclair RD. Disorders of hair. In: Burns DA, Breathnach SM, Cox N, Griffi ths CE, editors. Rook’s textbook of dermatology. 7th ed. Oxford, UK: Wiley-Blackwell; 2004; 63.1-63.120.

  11. Gilhar A, Paus R, Kalish RS. Lymphocytes, neuropeptides, and genes involved in alopecia areata. J Clin Invest 2007; 8: 2019-2027.

  12. Gupta MA, Gupta AK, Watteel GN. Stress and alopecia areata: a psychodermatologic study. Acta Derm Venereol 1997; 77: 296-298.

  13. Arck PC, Slominski A, Theoharides TC et al. Neuroimmunology of stress: skin takes center stage. J Invest Dermatol 2006; 126: 1697-1704.

  14. Peters EM, Botchkarev VA, Botchkareva NV et al. Hair-cycle-associated remodeling of the peptidergic innervation of murine skin, and hairgrowth modulation by neuropeptides. J Invest Dermatol 2001; 116: 236-245.

  15. Rossi R, Del Bianco E, Isolani D et al. Possible involvement of neuropeptidergic sensory nerves in alopecia areata. Neuroreport 1997; 24: 1135-1138.

  16. Siebenhaar F, Sharov AA, Peters EM et al. Substance P as animmunomodulatory neuropeptide in a mouse model for autoimmunehair loss (alopecia areata). J Invest Dermatol 2007; 127: 1489-1497.

  17. Alkhalifah A, Schwartz R, Janniger C. Alopecia areata update. Part II: Treatment. J Am Acad Dermatol 2010; 62: 191-201.

  18. Ehsani A, Toosi S, Seirafi H et al. Capsaicin versus clobetasol for the treatment of localized alopecia areata. J Eur Acad Dermatol Venereol 2009; 23(12): 1451-1453.

  19. Messenger A. British Association of Dermatologists’ guidelines for the management of alopecia areata 2012. British Association of Dermatologists 2012; 166: 916-926.

  20. Olsen E. Investigative guidelines for alopecia areata. Dermatologic Therapy 2011; 24: 311-319.

  21. Shapiro J, Madani S. Alopecia areata: diagnosis and management. Int J Dermatol 1999; 38(Suppl. 1): 19-24.

  22. Alkhalifah A, Alsantali A, Wang E, Alopecia areata update. Part I: Clinical picture, histopathology, and pathogenesis. J Am Acad Dermatol 2010; 62: 177-188.

  23. Madani S, Shapiro J. Alopecia areata update. J Am Acad Dermatol 2000; 42: 549-566.

  24. Price VH. Therapy of alopecia areata: on the cusp and in the future. J Investig Dermatol Symp Proc 2003; 8: 207-11.

  25. Delamere FM, Sladden MJ, Dobbins HM, Leonardi-Bee J. Interventions for alopecia areata. Cochrane Database of Systematic Reviews 2008, Issue 2. Art. No.: CD004413

  26. MacDonald HSP, Word ML, Hutchinson PE, Sladden M, Messenger AG. Guidelines for the management of alopecia areata. Br J Dermatol 2003; 149: 692-699.

  27. Tosti A. Therapies versus placebo in the treatment of patchy alopecia areata. J Am Acad Dermatol 1986; 15: 209-210.

  28. Groves N. Capsaicin bats .500: small study shows preliminary success in alopecia areata; more research needed. (Special Report). Dermatology Times 2002.

  29. Harada N, Okajima K, Arai M, Kurihara H, Nakagata N. Administration of capsaicin and isofl avone promotes hair growth by increasing insulin-like growth factor-I production in mice and in humans with alopecia. Growth Hormone & IGF Research 2007; 30: 1-7.




2020     |     www.medigraphic.com